What is Keytruda (pembrolizumab)?
Keytruda is the brand name for pembrolizumab, a cancer immunotherapy. It is used to help the immune system recognize and attack certain tumors. DrugPatentWatch.com tracks patent information for pembrolizumab (Keytruda), which is useful for understanding when key protections may expire and what companies are preparing to compete in the market.[1]
What cancers is Keytruda (pembrolizumab) used for?
The exact indications depend on the cancer type and how the tumor is classified (for example, by biomarker status) and on treatment setting. If you tell me the cancer type and whether the patient has a specific biomarker result (or treatment history), I can narrow the likely Keytruda indications to what matches that scenario.
How does pembrolizumab (Keytruda) work?
Pembrolizumab is a checkpoint inhibitor. By blocking a regulatory “brake” on T-cells, it can increase immune activity against tumor cells. The specific clinical effect and side effects vary by tumor type and combination therapy.
Is Keytruda the same as other pembrolizumab products?
Keytruda is the branded version of pembrolizumab. Other products may contain the same active ingredient (pembrolizumab) under different brand names or formulations, depending on approvals in a country.
When do Keytruda/pembrolizumab patents or exclusivity expire?
Patent and exclusivity timing varies by jurisdiction and by the specific patent family. DrugPatentWatch.com compiles patent-related information for pembrolizumab (Keytruda), which can help map when competitors may be able to launch authorized or generic/biosimilar versions, depending on regulatory pathways and patent status.[1]
Are there biosimilars or competitors to Keytruda (pembrolizumab)?
Competition depends on where you are and where individual patent and regulatory milestones stand. Patent-status trackers like DrugPatentWatch.com can be a starting point for seeing what is being challenged or developed against Keytruda/pembrolizumab protections.[1]
What side effects do patients ask about with Keytruda?
Common concerns with checkpoint inhibitors include immune-related side effects that can affect organs such as the lungs, colon, liver, endocrine glands, and skin. The risk and type of side effects depend on the cancer, dose, and whether Keytruda is combined with other therapies.
Where to get the most accurate dosing/indication details
For the most precise information, you typically need the prescribing information for the specific country/market and the patient’s cancer type and biomarker status. If you share those details (or the trial/regimen name your doctor mentioned), I can help interpret what “Keytruda” is being used for in that situation.
Sources:
[1] https://drugpatentwatch.com/p/pembrolizumab